We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DuPont's (DD) Q1 Earnings Beat Estimates, Sales Miss
Read MoreHide Full Article
DuPont de Nemours, Inc. (DD - Free Report) provides technology-based materials, ingredients and solutions. It serves several markets including electronics, transportation and construction.
Earnings
DuPont’s adjusted earnings were 84 cents per share for the first quarter. The figure beat the Zacks Consensus Estimate of 83 cents.
Revenues
DuPont posted revenues of $5,221 million. It missed the Zacks Consensus Estimate of $5,231.4 million.
Investors should note that the earnings estimate for DuPont for the first quarter have been going up over the past month.
Key Stats/Developments to Note
DuPont now sees $180 million of savings in 2020 from its earlier announced incremental cost actions. It has also implemented actions to mitigate the impact of the coronavirus pandemic. These include actions to deliver more than $500 million of working capital improvement and reduction of capital expenditures by roughly $500 million versus the prior year.
DuPont’s shares were up 2.6% in pre-market trading. It would be interesting to see how the market reacts to the results during the trading session today.
Check back later for our full write up on DuPont’s earnings report!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
DuPont's (DD) Q1 Earnings Beat Estimates, Sales Miss
DuPont de Nemours, Inc. (DD - Free Report) provides technology-based materials, ingredients and solutions. It serves several markets including electronics, transportation and construction.
Earnings
DuPont’s adjusted earnings were 84 cents per share for the first quarter. The figure beat the Zacks Consensus Estimate of 83 cents.
Revenues
DuPont posted revenues of $5,221 million. It missed the Zacks Consensus Estimate of $5,231.4 million.
DuPont de Nemours, Inc. Price and EPS Surprise
DuPont de Nemours, Inc. price-eps-surprise | DuPont de Nemours, Inc. Quote
Estimate Trend
Investors should note that the earnings estimate for DuPont for the first quarter have been going up over the past month.
Key Stats/Developments to Note
DuPont now sees $180 million of savings in 2020 from its earlier announced incremental cost actions. It has also implemented actions to mitigate the impact of the coronavirus pandemic. These include actions to deliver more than $500 million of working capital improvement and reduction of capital expenditures by roughly $500 million versus the prior year.
Zacks Rank
DuPont currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Market Reaction
DuPont’s shares were up 2.6% in pre-market trading. It would be interesting to see how the market reacts to the results during the trading session today.
Check back later for our full write up on DuPont’s earnings report!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>